Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

ProQR Therapeutics (PRQR) Equity Income (2019 - 2022)

ProQR Therapeutics' Equity Income history spans 2 years, with the latest figure at -$8978.7 for Q1 2022.

  • On a quarterly basis, Equity Income fell 106.96% to -$8978.7 in Q1 2022 year-over-year; TTM through Dec 2022 was -$8978.7, a 97.65% increase, with the full-year FY2022 number at -$8162.0, up 96.82% from a year prior.
  • Equity Income hit -$8978.7 in Q1 2022 for ProQR Therapeutics, up from -$97237.5 in the prior quarter.
  • Over the last five years, Equity Income for PRQR hit a ceiling of $129067.3 in Q1 2021 and a floor of -$257714.1 in Q2 2021.